peptide wiki

TB-500

aka TB4 fragment · Thymosin Beta-4 fragment

Healing & Recovery research-only

Mechanism

Synthetic fragment of Thymosin Beta-4 active site. Studied for actin sequestration, cell migration, and tissue repair.

Studied uses

Identification

CAS number885340-08-9
Molecular formulaC38H68N10O14
SequenceLKKTETQ
Typical dose2–5 mg/week subcutaneous (research only)
Half-life~2-3 hours

Safety

WADA-prohibited (S2 class). Not FDA-approved for human therapeutic use.

Vendors selling TB-500

VendorSizePriceListed purityTrust
Peptide Partners 65

Research

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Mendias CL, Awan TM · Sports Med (2026) · review
source →
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
Mayfield CK, Bolia IK, Feingold CL, et al. · Am J Sports Med (2026) · review
source →
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Rahman OF, Lee SJ, Seeds WA · J Am Acad Orthop Surg Glob Res Rev (2026) · review
source →
Comparative effects of dietary sodium butyrate and tributyrin on broiler chickens' performance, gene expression, intestinal histomorphometry, blood indices, and litter.
Ismael E, Kamel S, Elleithy EMM, et al. · Sci Rep (2025) · cohort
source →
Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.
Rahaman KA, Muresan AR, Min H, et al. · J Chromatogr B Analyt Technol Biomed Life Sci (2024) ·
source →
Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5.
Judák P, Van Eenoo P, Deventer K · Anal Biochem (2017) ·
source →
Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.
Thevis M, Schänzer W · J Pharm Biomed Anal (2014) · review
source →
Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.
Thevis M, Thomas A, Schänzer W · Expert Rev Proteomics (2014) ·
source →
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.
Esposito S, Deventer K, Goeman J, et al. · Drug Test Anal (2012) ·
source →
Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.
Ho EN, Kwok WH, Lau MY, et al. · J Chromatogr A (2012) ·
source →